Category Archives: DNA

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the three and nine months ended June 30, 2021.

We delivered excellent year-over-year revenue growth in the fiscal third quarter while laying the groundwork to secure a recently awarded COVID-19 testing services contract that has potential to be the largest contract in the Companys history, said Dr. James A. Hayward, president and CEO of Applied DNA. Demand for safeCircle, our pooled COVID-19 testing program, experienced a seasonal decline from the fiscal second quarter, reflecting the start of the summer recess months for our academic clients and progressively higher vaccination rates and lower positivity rates in our operating area. Our recent award from the City University of New York for large-scale turnkey COVID-19 testing services should continue to drive strong year-over-year revenue growth over the period of the contract.

Continued Dr. Hayward, Our operating activities during the quarter were distinguished by an expansion of our COVID-19 offerings to drive incremental revenue and to drive adoption of LinearDNA as an alternative to plasmids for nucleic acid-based therapies. Following constructive interactions with the U.S. Food and Drug Administration (FDA) as part of a preliminary Emergency Use Authorization application process and the evolving nature of the pandemic, we revised our Linea SARS-CoV-2 Mutation (the Linea Mutation Panel) (formerly SGS Mutation Panel) to target three SARS-CoV-2 mutations (E48K, L452R, N501Y) that have been designated substitutions (mutations) of therapeutic concern by the Centers for Disease Control and Prevention.

Should the FDA grant an EUA for the Linea Mutation Panel, we believe that it will offer clinical utility to healthcare systems by enabling precision COVID-19 treatment and commercial utility to monoclonal antibody manufacturers by better characterizing patients before treatments. In recent months, several monoclonal antibody treatments have had their EUA revoked or have demonstrated a reduction in efficacy on a standalone or in combination with other treatments due to mutational impact. Use of the Linea Mutation Panel is tied to our Linea COVID-19 Assay Kit to determine positivity in clinical samples that would drive additional Assay demand if the EUA is granted for our Mutation Panel. We believe that an EUA-authorized Linea Mutation Panel will also provide additional value to our existing COVID-19 testing customers and, when combined with our Whole Genome Sequencing assets, provide data of interest to epidemiologists.

Concurrently, the launch of our veterinary LinearDNA COVID-19 vaccine trial and the subsequently reported strong immune response that the vaccine candidate elicited, further reinforce the value proposition of LinearDNA, and, longer-term, generates invaluable preclinical data supporting the eventual application of LinearDNA to nucleic acid-based therapies in humans.

Concluded Dr. Hayward, Looking ahead, the confluence of increasing positivity rates due to the Delta variant, the commingling of vaccinated, partially vaccinated, and unvaccinated individuals, and new mandatory testing requirements for local and state-level employees in our operating area affirm the need for ongoing and consistent COVID-19 screening available through safeCircle. Subject to FDA's evolving EUA request review priorities, we expect to file shortly our formal request for EUA for our Linea Mutation Panel. In addition, in the coming weeks we intend to launch our COVID-19 veterinary vaccine candidate challenge trial in furtherance of a commercial animal health opportunity.

Regarding our supply chain security business, we have cautious optimism within the cotton supply chains we serve as we approach the start of the cotton ginning season in the U.S. However, with Asia-Pacific beset by the Delta variant, man-made fiber opportunities remain static. With the tailwind of COVID-19 testing at our back supplemented by continued execution on business development initiatives, we believe we are laying the foundation for sustainable growth.

Fiscal Third Quarter 2021 Financial Highlights:

Nine-Month Financial Highlights:

Fiscal Third Quarter 2021 Conference Call Information

The Company will hold a conference call and webcast to discuss its fiscal third quarter-end 2021 results on Thursday, August 12, 2021, at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors questions on the Q&A portion of the call, not all questions may be answered.

To Participate:

Live webcast: https://services.choruscall.com/mediaframe/webcast.html?webcastid=Bin1qa3n

Telephonic replay (available 1 hour following the conclusion of the live call through August 19, 2021):

The webcast and accompanying PowerPoint presentation will be archived on the IR Calendar and Corporate Presentations page listed under the Investor Relations drop-down menu on the Companys website.

About safeCircle

ADCLs high throughput pooled testing program, known as safeCircle, utilizes frequent, high-sensitivity pooled testing to help prevent virus spread by quickly identifying infections within a community, school, or workplace. safeCircle provides rapid results using real-time PCR (RT-PCR) testing.

Click through to learn more about how safeCircle can help your community, school, and workplace: safeCircle

About Linea COVID-19 Assay Kit and Linea SARS-CoV-2 Mutation Panel

The Linea COVID-19 Assay Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare provider (HCP). The test is also intended for use with anterior nasal swab specimens that are self-collected in the presence of an HCP from individuals without symptoms or other reasons to suspect COVID-19 when tested at least weekly and with no more than 168 hours between serially collected specimens.

The scope of the Linea COVID-19 Assay Kit EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUAs prior termination or revocation. The diagnostic kit has not been FDA cleared or approved, and the EUAs limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.

The Linea SARS-CoV-2 Mutation Panel (formally SGS Mutation Panel) (the Linea Mutation Panel) is for Research Use Only (RUO) and shall not be used for clinical diagnostic purposes. The Linea Mutation Panel has not been approved or authorized to diagnose, ameliorate and/or detect any disease by any U.S. or international regulatory authority.

Information about Non-GAAP Financial Measures

As used herein, GAAP refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a companys historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

EBITDA- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

Adjusted EBITDA- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle, a pooled COVID-19 testing program that is grounded in the Companys EUA-authorized Linea COVID-19 Assay Kit. safeCircle is designed to look for infection within defined populations or communities utilizing pooled testing methodologies that increase testing efficiencies. The Company has also developed and plans to seek EUA-authorization for its Linea SARS-CoV-2 Mutation Panel, an assay-based panel for the detection of certain SARS-CoV-2 genetic mutations.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW.

Applied DNA is a member of the Russell Microcap Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNAs future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown amount of revenues and profits that will result from any COVID-19 testing contract (including the testing contract with the City University of New York), limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNAs or its partners diagnostic or therapeutic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (U.S. FDA), the U.S. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA, the USDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, USDA, equivalent foreign regulatory agencies and/or the New York State Department of Health, the unknown limited duration of any Emergency Use Authorization (EUA) approval from U.S. FDA, changes in guidance promulgated by the CDC, FDA and/or CMS relating to COVID-19 testing, disruptions in the supply of raw materials and supplies, the unknown ability to manufacture the vaccine candidates in large quantities, the fact that the safety and efficacy of the vaccine candidates has not yet been established, the unknown ability of the vaccine candidates to generate revenue or profit for Applied DNA, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, and various other factors detailed from time to time in Applied DNAs SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, Quarterly Reports on Form 10-Q filed on February 11, 2021, May 13, 2021, and August 12, 2021 and other reports we file with the SEC, which are available at http://www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

APPLIED DNA SCIENCES, INC.CONSOLIDATED BALANCE SHEETS

June 30,

September 30,

2021

2020

ASSETS

(unaudited)

$

12,173,443

$

7,786,743

737,347

194,319

429,116

497,367

356,414

599,296

13,696,320

9,077,725

2,576,616

1,277,655

95,053

95,083

285,386

285,386

536,354

605,330

Read the original:
Applied DNA Announces Third Quarter Fiscal 2021 - Business Wire

The Ayta Magbukon people of the Bataan peninsula on Luzon Island, the Philippines, have the worlds highest proportion of Denisovan genes a new study has discovered, despite centuries of interbreeding with later arrivals to Luzon. The discovery reveals a fourth known encounter between Denisovans and modern humans. It also suggests the ancient humans who inhabited the islands of South East Asia may have been descendants of the Denisovans, and at least some of them may have also bred with modern humans.

Ancient humans such as Neanderthals and Denisovans have shaped the human genome through what geneticists call admixture, changing our immune systems and teeth.Indeed these genes are so common in modern humans as to created debate about whether these archaic humans should be considered subgroups of Homo Sapiens, rather than their original designation as different species. Homo floresiensis (nicknamed hobbits) and the recently discovered Homo luzonensis, on the other hand, have been considered more remote relations, most likely unconnected to us for hundreds of thousands of years.

Neanderthal genes are widespread outside Africa, but the Denisovan contribution to the genome is concentrated in South East Asia and Australia. Past studies have found allele (gene varieties) inherited from Denisovans are most common among Papuan Highlanders in what is now New Guinea and Indigenous Australians. However, a new paper in Current Biology reports something other researchers overlooked: an even higher Denisovan inheritance among the Ayta Magbukon, a Philippine Negrito ethnic group.

Philippine Negritos are thought to be the earliest human population to migrate to the Philippines. There are at least 30 self-identified Negrito groups, 25 of which were involved in this study. The researchers found the higher the Negrito ancestry a person had, the higher their Denisovan ancestry.

This discovery is surprising, and significant, because the Ayta Magbukon have had much more contact, and interbreeding, with the rest of the world than Papuan highlanders, who were largely isolated until very recently.

Philippine Negritos were recently admixed with East Asian-related groups who carry little Denisovan ancestry, and which consequently diluted their levels of Denisovan ancestry,said Dr Maximillian Larena of Uppsala University. Once Larena and co-authors accounted for such dilution they found theAyta Magbukononce had 30-40 percent more Denisovan ancestry than Papuans or Indigenous Australians. Admixture almost certainly occurred in the Philippines, in addition to the three previously identified encounters; two on the Asian mainland before people fanned out through the islands, and a more recent one in New Guinea or nearby.

Some other Luzon Indigenous populations also exceed Papuan levels of Denisovan DNA, but the Ayta Magbukon stand out.

Geneticists estimate the timing of admixture events from the length of DNA tracts left behind. The Ayta Magbukons Denisovan tracts are of similar length to those of Australasian peoples, indicating the admixture was not substantially more recent.

The paper notes no Denisovan fossils have been found in the Philippines (or indeed anywhere outside Siberia and Tibet). However, we know almost nothing about the ancestry of H. luzonensis. Perhaps, the authors suggest, the two were genetically related, and H. luzonensis were still present in Luzon when modern humans arrived.

This then raises the question of whether H. floresiensis, who appear to share many characteristics with H. luzonensis, might also have been of Denisovan descent. A people known to us only from four bones, and the DNA inside, may have adapted to many island environments and survived there for hundreds of thousands of years.

Earlier this year Larena and colleagues were accused of not complying with Philippine guidelines on informed consent from the people whose DNA they studied for previous work and not gaining proper ethical clearance. Larena and a colleague responded that independent investigations have cleared them of these allegations, but this has not satisfied some critics.

Receive our biggest science stories to your inbox weekly!

Read the original here:
Indigenous Group In The Philippines Has Most Denisovan DNA in the World - IFLScience

Little Hector Perez was hanging out on the baseball bleachers of Maslow Park with a group of about 15 kids when the car pulled up.

It was a calm, October night in 2001. The dark-colored Dodge Neon with four people inside rolled by at around 9:15 p.m. Someone pointed a gun out of a tinted, passenger window and opened fire.

The children scattered as roughly half a dozen bullets whizzed through the evening air. When they returned after the car left, they found 9-year-old Hector slumped over with a gunshot wound to his chest, police said. The fourth grader died at University Medical Center.

Witnesses did not get a good look at the shooter. Some did not talk to police. Investigators suspected gang involvement. About a month and a half later, then-homicide detective Sheila Huggins worried that the case would never be solved.

Random acts of violence are so hard to follow up, Huggins told the Las Vegas Review-Journal in November 2001.

Nearly 20 years later, the case remains open. It haunts Huggins to this day.

The cold case unit

Metros cold case unit is made up of five retired homicide detectives who work part-time on their pension to investigate unsolved killings, including Hectors.

Related: Inside Metros record-breaking cold case

Dan Long and Ken Hefner, who have been with the unit for 2.5 and 6 years, respectively, said there are common misconceptions about what makes a case cold. It does not get that distinction until the cases lead detective retires. Even then, another detective may choose to take it on until they retire.

As former homicide detectives, we know there are times where youre more of a fireman than a detective, Hefner said, describing working on cases that cropped up earlier in his career like putting out fires left and right.

The cold case unit affords its investigators more time to dig deep, allowing seasoned detectives with the instinct and training needed to solve a killing the freedom to work without the pressure of a constantly climbing caseload.

Still, as time passes, witnesses move or die. Memories can falter.

The most likely thing thats going to solve our cases is DNA, Long said.

And advancements in technology are giving decades-old samples new promise.

The promise of DNA

Last month, Las Vegas police announced that the cold case unit had identified a suspect in the 1989 strangulation of local teen Stephanie Isaacson using a mere 15 cells of DNA evidence. It set a world record for the smallest amount of DNA ever used to help solve a crime.

The same sample had been run several times over the years through a DNA database maintained by the FBI, but never saw a match. The latest lead came from genome sequencing, a type of DNA testing that utilizes family trees and shared DNA between relatives to help identify possible suspects. The same testing identified Californias since-convicted Golden State Killer in 2018.

Now, Metro cold case detectives think another development in DNA technology called phenotyping could help solve the 2004 slaying of Theresa Insana, a 26-year-old sales executive for the Rio who was killed in her Summerlin home.

Police at the time of Insanas death said there were no signs of forced entry at her house. Her car was still there and her purse, keys, credit cards and cocker spaniel puppy were all inside. Her remains were found a few miles away, near what was then a drainage culvert at Hualapai and Peace ways.

She was in her house minding her own damn business and somehow, somebody comes in and kills her, Hefner said. She was one of those truly innocent victims.

Carol Palazzo, Insanas cousin, says the family has fought tirelessly to find Insanas killer in the nearly two decades since her death. Insanas father died in April, but her mother still calls Metro every Monday, begging them not to forget about her baby girl.

Theyve looked into all kinds of leads, and theyve run the DNA, but nothing ever panned out and its been 17 years, Palazzo said. Its left a huge void in our family.

Critics have doubts

Proponents of phenotyping say it allows analysts to reverse-engineer a persons physical profile based on a DNA sample. Using the method, Metro has a composite image of what Insanas killer may have looked like.

CeCe Moore, chief genetic genealogist at Virginia-based Parabon NanoLabs, which offers a phenotyping service to law enforcement agencies, said phenotyping isnt used to create an exact image, but rather to provide a list of physical attributes that investigators like Hefner can use to narrow down their suspect search.

Some scientists, like Kenneth Kidd, are skeptical of the services credibility. Kidd, a retired Yale University genetics professor, said one of his main concerns is that Parabon NanoLabs research has not been published in peer-reviewed journals to validate its methods.

As a rigorous scientist, I just cant accept it, Kidd said.

Moore said Parabon NanoLabs hasnt published its work in a peer-reviewed journal because the company doesnt want to give out proprietary information.

Theyve spent a lot of money developing these predictions, and if you publish it in a peer-reviewed journal, youve just given away all of your trade secrets, Moore said, adding that the companys record of success speaks for itself.

Without divulging further details, Hefner said the phenotyping result has him confident Insanas case could be solved.

Limitations

Hectors case is harder. There was no physical contact from his killer.

Police did collect DNA evidence from an unspent cartridge found at the park. But a long-awaited match could only tell investigators who loaded the weapons magazine, not who fired the gun, bringing detectives right back to the drawing board.

The promise of DNA has its pitfalls, too.

You hope that someday, somebody will have the guts to say something, Huggins, the detective who originally worked Hectors case, said this month.

Following Hectors death, the little boys family held out hope that his killer would be found. His older brother, Robert Perez, was at the park when he was shot. He told the Review-Journal in November 2001 that he had trouble sleeping at night.

Hectors older sister, Cecilia Martinez, told the Review-Journal in 2002 that she was hopeful someone would come forward.

Its still hard to believe this happened, she said at the time. Its hard not seeing him every morning.

Attempts to reach the Perez family for this story were not successful.

Crime scenes from other cold cases have been lost to development, but Maslow Park still stands. A memorial marker was dedicated to Hector there on May 31, 2002 a plaque near the ball fields where he bled out. Even that is gone now, though. Removed or stolen, but never replaced.

Contact Alexis Ford at aford@reviewjournal.com or 702-383-0335. Follow @alexisdford on Twitter.

More:
Detectives see new promise in long-shelved DNA. But there are pitfalls. - Las Vegas Review-Journal

DUBLIN, August 10, 2021--(BUSINESS WIRE)--The "DNA/RNA Extraction Kit Market - Growth, Trends, COVID-19 Impact, and Forecast (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The DNA/RNA extraction kit market is expected to register a CAGR of 7.26% during the forecast period of 2021-2026.

The COVID-19 pandemic impacted the DNA/RNA extraction kit market for the short time being due to restrictions on different business and research activities. Also, the diagnostics tests of other diseases and medical disorders in the hospitals and other clinical diagnostics establishments were affected due to a decrease in the turnout of the patients for tests because of COVID-19. But the high infection rate of COVID-19 and research activities by the key companies in the area of sequencing to expand their knowledge about the virus and its origin along with molecular diagnostics of the SARS-CoV-2 virus led to the development and launch of many DNA and RNA based COVID-19 kits, which proved to be very crucial and were in huge demand later. For instance, in April 2020, PHASE Scientific announced the commercial launch of the PHASIFY VIRAL RNA extraction kit for the detection of the COVID-19 virus, globally.

The major driving factor behind the growth of the DNA/RNA extraction kit market is the increasing investments in the research and development activities in different fields including molecular diagnostics for different chronic and infectious diseases. For example, according to the Organization for Economic Co-operation and Development, in 2018, the United States spent USD 552 billion on the research and development activities followed by China with USD 463 billion. The technological advancements, launch of new products by the key market players, and rising cases of cancer around the world will also complement the growth of the studied market. For instance, June 2020, Omega Bio-tek, Inc. announced the launch of an advanced viral RNA extraction kit for the COVID-19 testing, called Mag-Bind Viral RNA Xpress kit for the efficient extraction of the Viral RNA from nasopharyngeal (NP) swab samples.

Story continues

Other factors such as increased demand in the automation of DNA/RNA extraction technology, new user friendly and easy extraction kits, use of DNA/RNA in the profiling of new diseases causing microorganism will also boost the growth of the DNA/RNA extraction kit market during the forecast period. While the low awareness and availability of the kits and less market penetration in the underdeveloped and developing regions around the world are the major restraining factors for the growth of the DNA/RNA extraction kit market.

Extraction Kits for Cancer Patients for Diagnosis and Identification Will Occupy a Significant Share in the Market over the Forecast Period

In the body of a patient suffering from any kind of cancer, circulating cell-free DNA (ccfDNA) which originates from cancer cells are found in the bloodstream and thus are called circulating tumor DNA (ctDNA). A very sensitive RNA and DNA extraction kits are used to isolate and profile them and based on which treatment is performed on the patient. The companies are working towards it and developing and launching products related to the area. For instance, in May 2018, BioChain Institute Inc. launched a new cell-free DNA extraction kit called cfPure for the efficient isolation and detection of circulating cell-free DNA (ccfDNA).

According to the International Agency for Research on Cancer (IARC) data released in December 2020, about 1 in 5 people develops cancer in their lifetime, and 1 in 8 men and 1 in 11 women die from cancer, globally. As per its updated GLOBOCAN 2020 report, in 2020 there were about 19.3 million new cancer cases around the world and 10 million people died from it. So, the increasing prevalence of cancer will boost the growth of the DNA/RNA extraction kit market.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

5 MARKET SEGMENTATION

6 COMPETITIVE LANDSCAPE

Qiagen

ThermoFisher Scientific Inc.

F. Hoffmann-La Roche AG

Agilent Technologies

Bio-Rad Laboratories, Inc.

Promega Corporation

Danaher Corporation (Beckman Coulter Inc.)

Merck & Co. Inc.

PerkinElmer Inc.

bioMerieux SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/71ytvk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005651/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:
Global DNA/RNA Extraction Kit Market 2021-2026: Extraction Kits for Cancer Patients for Diagnosis and Identification Forecast to Occupy a Significant...

Just about everything is different this year for the 2021 New Orleans Saints after the prolonged era of Drew Brees. In a way, the acceptance is now on the doorstep going into training camp. Currently, the quarterback battles is ongoing, although the overwhelming favorite is no doubt Jameis Winston. Yet, nothing is certain in the NFL. One play can change the course of a career. One injury could impact the duration of playing time, versus holding a clipboard forever. But make no mistake, Winstons faith is all he needs.

The evolution of quarterback Jameis Winston is not exactly related to the football field. Oh it is important. The game of football has provided a life for him and his family beyond most players dreams.

At a recent practice, a reporter asked You sound like a pastor, is that the way youve always been? Perhaps Winston is not a bonafide pastor but his heightened insight into lifes lessons are relatable to many.

The walk of many Christians on and off the field is never a straight road. Winston has been upfront about his testimony. His unwavering dedication to God has changed over the years. Just like many of us.

However, many of us non-football players likely did not win a Heisman Trophy or a national championship. Also, being under a microscope can show the best and worse in people. And Jameis Winston is at peace with pleasing God before anyone else. The brokenness he has been through may be the one thing that works in his favor the most.

When Jameis Winston shared his testimony with Austin Carr recently, a whole new DNA was exposed the world. You have to be broken to rebound, was one of the best quotes Winston offered to Carr regarding adversity. If you look at all the figures in scripture, they had to be broken before they were blessed.

Evidently, there is a lot more to Winston than some of his successes and failures on the field. Many fans see players on the field act a certain way versus the real person off of the field. Some may not even care. Regardless, Jameis Winstons whole make up and faith is a part of his identity on and off the field present day.

In response to the question if he had always had the prose of a pastor, Winston responded, Ive always been optimistic, but sometimes I have been too optimistic, right, Winston said. I think I had to fine tune that just understanding reality. My gratitude was built from my father, from my mother. I had some humble beginnings and you talk about a pastor, like, I know my Lord and Savior got me.

Winston has matured over the years. Giving the reason for his successes come from somewhere bigger than him. In other words, Winston knows he cannot do it alone. And he laid it out profoundly to everyone to what moves him.

This makes him a better man and even a father or husband. Does this guarantee success on the field? Of course not. Even Tim Tebow could not promise divine intervention in between the hash marks. Still, doubt him and his beliefs then question Drew Brees. Brees often talked about his walk with Christ too.

There are other Christians whom too etch their game in faith: Russell Wilson, Patrick Mahomes, and former quarterback Phillip Rivers, to name a few. While this is true, a portion of those teams fans are not fanatical about players talking about their faith loudly.

Winston is his own man. He has his own walk. Whether that walk off the field will be a winner when all is said is done, only God knows.

Main Image:

Embed from Getty Images

Originally posted here:
Jameis Winstons DNA is Etched in Stone with Unwavering Faith - Last Word on Pro Football

STEUBEN COUNTY, Ind. (Fort Wayne's NBC) - Court documents sayDNA evidenceat the scene of the murder of 82-year-old Wilma Ballled to the charging of 29-year-old Matthew Hoover.

Steuben County Chief Deputy Michael Meeks says without the advanced technologyused to match the DNA found inside the Lake James home, hesnot sure a suspect would have been charged this soon.

Meeks says DNA analysis has revolutionized criminal investigations like this one.

"Its a game changer when it comes to identifying suspects, Meeks said."The chances of a case being solved now is greatly elevated compared to 30 or 40 years ago.

He saysits almost impossiblefor a perpetratornot to leaveDNAevidencebehind.

"Somethings always taken from the crime scene, and somethings always left, he said.

Court documents sayHoover left behind two beer cansand investigators sent them to theIndianaStatePolice lab forthe DNAanalysis.

Matching a suspect profile to something from the scene, its this person and the chances of it being another person is like 1 in 8 trillion, Meeks said. Theyre pretty certain its this person.

Meeks says todays technology can even analyze microscopic DNA.

"It all started back in the late 80susing DNA fora criminal case, and back then it was only blood DNA, he said.Now,fast forward to today, you can trace with pretty much any bodily fluid.

Meeks says its important that they continue to develop betterDNAtracingto bring justice to more families.

"Unfortunately,theres nothing we can do to bring the victim back, but we can do everything we can to bring justice, he said.

Meeks says at their Steuben County jail they take DNA samples from every person who is arrested for their DNA tracing database.

Matthew Hoovers trial date is set for November 29th.

Read more:
Steuben County Sheriff explains the importance of DNA analysis in Lake James murder - Fort Wayne's NBC

A study of more than 45,000 people with COVID-19 has uncovered 13 genetic variants linked to an increased risk of infection with SARS-CoV-2 or a higher chance of developing severe illness, researchers report July 8 in Nature. The team includes more than 3,300 researchers in 25 countries.

Some of the variants had been uncovered in previous studies. For instance, researchers again confirmed a genetic link between blood type and the likelihood of getting infected, but dont know why people with type O blood may be slightly protected. The study also verified that a variant that disables the TYK2 gene raises the risk of critical illness and hospitalization. That variant is known to protect against autoimmune disease, but leaves people more vulnerable to tuberculosis.

But at least one association was unknown: A variant in a gene called FOXP4 is associated with more severe COVID-19, the team found. That variant boosts the genes activity and has been previously linked to lung cancer and interstitial lung disease, a group of diseases that cause scarring and stiffness of the lungs. Yet-to-be-developed drugs that inhibit activity of FOXP4s protein might help people recover from COVID-19 or prevent them from becoming very ill.

The disease-associated version of the gene is more common among Asians and Latino populations in the Americas, geneticist Mark Daly said July 7 during a news briefing. This link might never have been discovered if people of diverse ancestries from around the world hadnt been included in the study, said Daly, of the Institute of Molecular Medicine Finland in Helsinki (SN: 3/4/21). Only 2 percent to 3 percent of people with European ancestry carry the variant, compared with 7 percent of people in the Middle East, 20 percent of Latinos in the Americas and 32 percent of East Asians.

Originally published by Science News, a nonprofit newsroom. Republished here with permission.

Continue reading here:
How Your DNA May Affect Whether You Get COVID-19 or Become Gravely Ill - Cleveland Scene

TLDR: The DNA My Dog Breed Identification Test can give you all the inside scoop on your dogs insides, the genetics and health tips that can keep them happy and healthy for years.

You may be married. You may have a significant other. You may have a child. You may have several children. Your life may be packed to the rafters with family, friends, co-workers, and others to help fill your days.

But admit it there are times when your favorite living thing on the planet isnt a human. Its that buoyant, energetic bundle of fur and enthusiasm who hates when you leave, cant wait for you to get home, and would gladly spend every minute of the day with you if youd let them.

But considering a quarter of the dogs living in U.S. households today were shelter adoptions, theres a good chance you know precious little about whats inside the creature who cares so much about you. With a DNA My Dog Breed Identification Test ($50, 36 percent off, from TNW Deals), you can correct that error.

If youve ever taken a DNA test yourself, then you know the procedure. Just swab the DNA My Dog applicator inside your dogs cheek, bag it, and send it in for your results. About two weeks later, youll get back a detailed breakdown on your dog, a canine biography that uncovers everything you didnt know about the exact genetic makeup of your pooch.

And this isnt just for idle curiosity either. Knowing about your dogs background can offer all kinds of vital information about your pals potential genetic health concerns, the diseases the breed could be susceptible to, and all the personality and behavioral traits that breed is known for.

Armed with your dogs DNA, youll have an inside track on doing what you could never do before: help combat health problems before they become problems. You can tailor your dogs diet to help supplement deficiencies or be on the lookout for illnesses or medical conditions that could lead to long-term issues.

A winner of 2020 DogWellNet.com and GHP Biotechnology awards, the DNA My Dog Breed Identification Test is now available at over 35 percent off the regular price, offering a roadmap to your dogs future health and happiness for just $50.

Prices are subject to change

Go here to read the rest:
DNA My Dog gives you the full 411 on your canines genetic makeup - The Next Web

The 2,600-year-old rock-cut tombs of Al-Khuraiba, in Saudi Arabia.Image: FAYEZ NURELDINE/AFP (Getty Images)

A team of geneticists has sequenced 137 modern human genomes from the Middle East, shedding new light on how humans arrived in the region and how those populations changed as areas dried up.

The research goes a long way in a region where precious little is left of a fossil record. The recent aridification of the Arabian peninsula, especially, means that bones can get so brittle they can simply disintegrate when archaeologists pick them up, as Mathew Stewart, a zooarchaeologist at the Max Planck Institute for the Study of Human History, recently told Gizmodo. Genetic evidence is easily lost to time. The teams results draw on modern samples from eight different groups in the Levant, Iraq, and Arabia. Ancient genomes that had previously been constructed were also included in their analysis, which is published this week in the journal Cell.

The Middle East is an important region to understand human history, migrations, and evolution: it is where modern humans first expanded out of Africa, where hunter-gatherers first settled and transitioned into farmers, where the first writing systems developed, and where the first major known civilizations emerged, said Mohamed Almarri, a geneticist at the Sanger Institute in England and lead author of the study, in a Cell press release. However, despite this importance, the region has been historically understudied in genomic studies.

Expansions out of Africa, agricultural developments, and even climatological events can be interpreted from the genomic data, Almarris team said. Looking at ancient genomes from past Middle Eastern populations, the team determined that populations were able to grow as people began to settle down and started farming.

A Palestinian farmer on the West Bank in June 2020.Photo: HAZEM BADER/AFP (Getty Images)

G/O Media may get a commission

The researchers used a relatively new sequencing approach, called linked-read sequencing, that allowed them to reconstruct population histories as far back as 100,000 years ago. Geneticists can use the approach to analyze more of the genome, in this case identifying millions of genetic variants unique to Middle Eastern populations.

The researchers found that Middle Easterners descend from a population that left Africa between 50,000 and 60,000 years ago. That makes a mini-mystery of the 88,000-year-old human finger bone found at a prehistoric lake site in Saudi Arabia; it may be that bone belonged to a human group that dispersed early and did not contribute to the modern gene pool in the region. Many anatomically modern humans left Africa earlier, but these genetics suggest that modern Middle Eastern populations descended from the group that left Africa around 50,000 years ago.

Our study fills a major gap in international genomic projects by cataloguing genetic variation in the Middle East, said co-author Chris Tyler-Smith, also a geneticist at the Wellcome Sanger Institute, in the Cell release. The millions of new variants we found in our study will improve future medical association studies in the region. Our results explain how the genetics of Middle Easterners formed over time, providing new insights, which complement knowledge from archaeology, anthropology, and linguistics.

A satellite image of Saudi Arabia and environs in June 2007.Photo: NOAA (Getty Images)

Almarri and his co-author Marc Haber, a geneticist at the University of Birmingham in England, said in an email that a benefit of the research is being able to connect archaeological and ancient climate data with shifts in local population genetics. Population bottlenecks in Arabia 6,000 years ago and in the Levant 4,200 years ago point to moments when the verdant east began to dry up, the study authors said, with rapid aridification causing decreases in population sizes.

Based on when different groups mixed thousands of years ago, the team also evaluated how Semitic languages might have spread beyond the Levant, specifically pointing to the Bronze Age as a major point of intermixing, based on coincident timing between some of the genetic variations and previously determined dates for language divergence and evolution. The researchers also noted that Arabian populations have a much lower amount of Neanderthal ancestry than other Eurasians, indicating there was less admixture between our extinct close relatives and Arabian humans.

It is exciting to see so much new genomic data from a crucial part of the world. It is interesting to see the genetic coherence of recent social groups, and, as the authors say, for things like understanding modern health, it is important to have good sampling of people around the world, Huw Groucutt, a paleoanthropologist at the Max Planck Institute for the Science of Human History who wasnt involved with the recent study, said in an email. He added, however,that there are limitations to genomic studies and that the recent teams interpretations should be considered just that.

The team intends to follow up the research with a look at adaptation signals in the dataset, which could indicate how populations in the Middle East learned to survive in their environments when the region dried up. The recent discovery of a trove of animal bones, including human remains, in a Saudi lava tube will likely help in efforts flesh out this genetic portrait of the Middle East.

More: Hyenas Left a Massive Pile of Bones in a Saudi Arabian Lava Tube

View post:
Study of Middle East DNA Reveals Complex Human History in the Region - Gizmodo

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2021 third quarter financial results after market close on Thursday, August 12, 2021. The Companys management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. EDT that same day. Presentation slides will also be posted to the IR Calendar and Corporate Presentations sub-page of the Companys corporate website and embedded into the live webcast.

Conference Call and Webcast Information - Live

Conference Call and Webcast Information - Replay

A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.

The webcast and accompanying PowerPoint presentation will also be archived on the IR Calendar and Corporate Presentations page listed under the Investor Relations drop-down menu on the Companys website.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA is also the manufacturer of the EUA-authorized Linea COVID-19 Assay Kit.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include Gov/Mil, textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW.

Applied DNA is a member of the Russell Microcap Index.

Read more from the original source:
Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results Conference Call and Webcast for Thursday, August 12, 2021 - Business Wire